Stockreport

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Nuvation Bio Inc. Class A  (NUVB) 
PDF NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced [Read more]